Loading…
Relevance of genomic diversity of Mycobacterium tuberculosis complex in Africa
•Comparative genomics studies of MTBC shows significant genomic diversity.•MTBC genomic diversity has significant implications on phenotypic profiles.•MTBC diversity is relevant in the design of new control tools.•Diversity in MTBC must be considered in choice of future clinical trial sites. The div...
Saved in:
Published in: | International journal of infectious diseases 2022-11, Vol.124, p.S47-S49 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | •Comparative genomics studies of MTBC shows significant genomic diversity.•MTBC genomic diversity has significant implications on phenotypic profiles.•MTBC diversity is relevant in the design of new control tools.•Diversity in MTBC must be considered in choice of future clinical trial sites.
The diversity in the lineages of Mycobacterium tuberculosis complex (MTBC) was initially considered insignificant. However, comparative genomics analysis of MTBC have found genomic variation among the genotypes with potential phenotypic implications.
Therefore, this viewpoint seeks to discuss the impact of the identified genotypic diversity on the physiology of MTBC and the potential implications on TB control.
Studies conducted in West Africa and other parts of Africa have unravelled the implications of the genomic diversity on phenotypes such as disease outcome, transmission dynamics and host immune response. The understanding of the phenotypic diversity among the different lineages of MTBC may be an important key to the fight against TB.
The relevance of these differences has been observed in the design of new control tools such as diagnostics and anti-TB drugs/vaccines. This only points to the fact that the diversity in MTBC cannot be ignored in future studies especially clinical trials for new vaccines and new anti-TB drugs. |
---|---|
ISSN: | 1201-9712 1878-3511 1878-3511 |
DOI: | 10.1016/j.ijid.2022.03.016 |